About Blog News & Events Knowledge Center Glossary & FAQs Case Studies

About Blog News & Events Knowledge Center

Blog Posts

Oligonucleotide-based Drugs: a Promising Class of New Therapeutics?

Thursday 2nd December 2021

Thinking About LC-MS for HCP Quantitation?

Tuesday 23rd November 2021

Analysis of Adeno-Associated Virus (AAV) Capsid Proteins

Friday 13th August 2021

Two Steps Forward for Biosimilars in the US: The Approval of Interchangeable Semglee®

Wednesday 11th August 2021

“Gene Therapy – Game changer treatments” – Dr. Fiona Greer

Friday 4th June 2021

“US FDA Biosimilar Regulatory Developments in 2020”- Dr. Fiona Greer

Thursday 1st April 2021

Dealing with the Challenges of Disulfide Bridge Analysis in Biopharmaceuticals

Wednesday 17th March 2021

Guest Blog: “A Brexit Bonus for Biosimilars in the UK?” – Dr. Fiona Greer

Thursday 21st January 2021

Dealing with the challenges of N-glycan structures in complex glycoproteins

Wednesday 13th January 2021

Guest Blog: “Analytical R&D: Thoughts on Outsourcing vs In-house” – Dr. Fiona Greer

Wednesday 13th January 2021

Building Orthogonality into Your Analytical and Characterization Plans – Part 2

Friday 20th March 2020

Building Orthogonality into Your Analytical and Characterization Plans – Part 1

Monday 24th February 2020

Biosimilar Testing: Structural and Physico-Chemical Comparability Analysis

Thursday 30th January 2020

Protein Characterization Services to Support the Development of New Biopharmaceutical Products

Friday 13th December 2019

img.wp-smiley,img.emoji{display:inline !important;border:none !important;box-shadow:none !important;height:1em !important;width:1em !important;margin:0 .07em !important;vertical-align:-.1em !important;background:none !important;padding:0 !important;}.cli-modal-content,.cli-tab-content{background-color:#fff;}.cli-privacy-content-text,.cli-modal .cli-modal-dialog,.cli-tab-container p,a.cli-privacy-readmore{color:#000;}.cli-tab-header{background-color:#f2f2f2;}.cli-tab-header,.cli-tab-header a.cli-nav-link,span.cli-necessary-caption,.cli-switch .cli-slider:after{color:#000;}.cli-switch .cli-slider:before{background-color:#fff;}.cli-switch input:checked + .cli-slider:before{background-color:#fff;}.cli-switch .cli-slider{background-color:#e3e1e8;}.cli-switch input:checked + .cli-slider{background-color:#28a745;}.cli-modal-close svg{fill:#000;}.cli-tab-footer .wt-cli-privacy-accept-all-btn{background-color:#00acad;color:#fff;}.cli-tab-footer .wt-cli-privacy-accept-btn{background-color:#00acad;color:#fff;}.cli-tab-header a:before{border-right:1px solid #000;border-bottom:1px solid #000;}.breadcrumb{list-style:none;margin:0;}.breadcrumb li{margin:0;display:inline;position:relative;}.breadcrumb li::after{content:" > ";}.breadcrumb li:last-child::after{display:none;}